Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years

Annals of Hematology

Volumn 95, Issue 5, 2016, Pages 757-763

  Poggi, Maurizio ^a   Sorrentino, Francesco ^b   Pugliese, Pellegrina ^c   Smacchia, Maria Paola ^c   Daniele, Carmine ^d   Equitani, Francesco ^e   Terlizzi, Filomena ^f   Guitarrini, Maria Rita ^g   Monti, Salvatore ^a   Maffei, Laura ^b   Losardo, Anna ^c   Pasin, Methap ^d   Toscano, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b S EUGENIO HOSPITAL   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

^d SANDRO PERTINI HOSPITAL   (Italy)

^e SANTA MARIA GORETTI HOSPITAL   (Italy)

^f SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^g BELCOLLE HOSPITAL   (Italy)

Author keywords

Diabetes; Hypogonadism; Hypothyroidism; Iron overload; Osteoporosis

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON CHELATING AGENT; BENZOIC ACID DERIVATIVE; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BONE DENSITY; DIABETES MELLITUS; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOCRINE BONE DISEASE; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON CHELATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; THALASSEMIA MAJOR; ADVERSE EFFECTS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; COMBINATION DRUG THERAPY; COMPLICATION; FOLLOW UP; IRON OVERLOAD; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; BENZOATES; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; DEFEROXAMINE; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGONADISM; HYPOTHYROIDISM; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; PYRIDONES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 84960099749     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-016-2633-y     Document Type: Article

References (15)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89:1187–1193
2. Habeb AM, Al-Hawsawi ZM, Morsy MM, Al-Harbi AM, Osilan AS, Al-Magamsi MS, Zolaly MA (2013) Endocrinopathies in beta-thalassemia major. Prevalence, risk factors, and age at diagnosis in Northwest Saudi Arabia. Saudi Med J 34:67–73
3. Gamberini MR, De Sanctis V, Gilli G (2008) Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev 6(Suppl 1):158–169
4. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, Thalassemia Clinical Research N (2004) Complications of beta-thalassemia major in North America. Blood 104:34–39
5. Noetzli LJ, Panigrahy A, Mittelman SD, Hyderi A, Dongelyan A, Coates TD, Wood JC (2012) Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol 87:167–171
6. Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC (2012) Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 87:155–160
7. Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT (2012) Serum ferritin levels and endocrinopathy in medically treated patients with beta thalassemia major. Ann Hematol 91:1107–1114
8. Haidar R, Musallam KM, Taher AT (2011) Bone disease and skeletal complications in patients with beta thalassemia major. Bone 48:425–432
9. Casale M, Citarella S, Filosa A, De Michele E, Palmieri F, Ragozzino A, Amendola G, Pugliese U, Tartaglione I, Della Rocca F, Cinque P, Nobili B, Perrotta S (2014) Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with beta-thalassemia major. Am J Hematol 89:1102–1106
10. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V (2010) Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 148:466–475
11. Farmaki K, Tzoumari I, Pappa C (2011) Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis 47:33–40
12. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y (2011) Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up. Blood 118:884–893
13. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A (2012) Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major. Haematologica 97:842–848
14. Deugnier Y, Turlin B, Ropert M, Cappellini MD, Porter JB, Giannone V, Zhang Y, Griffel L, Brissot P (2011) Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years. Gastroenterology 141:1202–1211
15. Forni GL, Podesta M, Musso M, Piaggio G, Musallam KM, Balocco M, Pozzi S, Rosa A, Frassoni F (2013) Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with beta-thalassemia major. Haematologica 98:555–559